Abstract 206TiP
Background
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is frequently diagnosed at an advanced stage. In the phase 3 HIMALAYA study (NCT03298451) in unresectable HCC (uHCC), the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen improved overall survival (OS) versus sorafenib, with a manageable safety profile. HIMALAYA enrolled participants with uHCC not eligible for embolisation with Barcelona Clinic Liver Cancer (BCLC) stage B or C, Child-Pugh (CP) class A, WHO/ECOG PS of 0-1 and no main trunk portal vein thrombosis (PVT). Based on the positive results of HIMALAYA, the aim of SIERRA is to assess the safety and efficacy of STRIDE in a broader uHCC population, including inferior hepatic function, poorer performance status or more advanced disease.
Trial design
SIERRA (NCT05883644) is a phase 3b, single-arm, multicentre study. This study will enroll approximately 140 adults with uHCC, BCLC stage B or C, and one of the following: CP class of B7 or B8 with WHO/ECOG PS of 0-1, without main trunk PVT; CP class A with WHO/ECOG PS of 2, without main trunk PVT; CP class A with WHO/ECOG PS of 0-1 with evidence of chronic main trunk PVT. Participants must not have received prior systemic therapy for HCC and must not be eligible for locoregional therapy. Key exclusion criteria include evidence of acute main trunk PVT. All participants will receive STRIDE: one single priming dose of 300 mg tremelimumab plus 1500 mg durvalumab at Day 1 (Week 0), followed by durvalumab 1500 mg monotherapy Q4W starting at Week 4 and continuing until clinical progression, confirmed radiological progression (RECIST 1.1), unacceptable toxicity, withdrawal of consent or any discontinuation criteria are met. The co-primary endpoints are the incidence of Grade 3 or 4 adverse events possibly related to study intervention within 6 months after initiation of STRIDE and investigator-assessed (RECIST 1.1) objective response rate. Secondary endpoints include OS, progression-free survival, duration of response and health-related quality of life. Enrolment has begun and will proceed in France, Germany, Italy, Japan, South Korea, Singapore, Spain, United States, Vietnam and Hong Kong.
Clinical trial identification
NCT05883644.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
S.L. Chan: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, MSD, BMS, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Personal, Research Grant: Eisai, MSD. B. Sangro: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Boston Scientific, Roche, Sirtex, Terumo, Bayer, Adaptimmune; Financial Interests, Personal, Invited Speaker: Roche, Sirtex, Eisai, Ipsen, Incyte, AstraZeneca, Astellas Pharma; Financial Interests, Institutional, Research Grant: BMS, Sirtex; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal, Steering Committee Member: BMS, Boston Scientific, Roche. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. A. Dane: Financial Interests, Institutional, Speaker, Consultant, Advisor: Adagio, Amplyx, AN2, Bioscript, Bugworks, CARBX, Closed Loop Medicine, Correvio, Davolterra, Destiny, Evopoint, F2G, Entasis, Gates, GSK, Humanigen, Liverpool University, Kymab, Melinta, Modis, Orca, Phico, Quince, Roche, SFunga, Scynexis, Sinovent, SNIPR; Financial Interests, Institutional, Other, Independent statistician on DSMBs: Aridis, Cerium, ContraFect, Egetis, Midatech, Pfizer, Pled, Rare Thyroid, Sanofi, Transcrip. C. Emery: Financial Interests, Personal, Other, Contracted employee: AstraZeneca. M. Paskow: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Makowsky: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. B. Nguyen: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Bayer, BMS, Incyte, Ipsen, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene, Zymeworks; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Coordinating PI, European PI: AstraZeneca.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract